Description
MIF098 is a macrophage migration inhibitory factor ( MIF ) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research.In VitroMIF098 (0-10 µM, 48 h) inhibits mPASMC cell proliferation and migration in a concentration-dependent manner, by blocking the migration inhibitory factor (MIF) pathway. MIF098 reduces collagen synthesis and pulmonary artery fibrosis by inhibiting the TGFβ1/Smad2/3 pathway. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Mouse pulmonary artery smooth muscle cells (mPASMCs) Concentration: 0-10 µM Incubation Time: 48 hours Result: Reduced expression of cell cycle related proteins such as cyclin D1, CDK4 and CDK6 in PDGF-BB and increased expression of cell-cycle arrest proteins such as P53 and P21. Reduced TGFβ1-induced fibronectin (FN), collagen I (col I), and collagen II (col II) expression and phosphorylation of Smad2 and Smad3.In VivoMIF098 (intraperitoneal injection, 40 mg/kg, once a day, 4 weeks) attenuates the process of hypoxia-induced pulmonary arterial hypertension in C57BL/6J mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Hypoxic male C57BL/6J mice Dosage: 40 mg/kg Administration: Intraperitoneal injection; once a day; 4 weeks Result: Reduced right ventricular systolic pressure (RVSP), percentage medial wall thickness, muscularization and right ventricle collagen deposition. Decreased percentage of collagen fibers in pulmonary artery (PA).Form:Solid